|
1
|
Samii A, Nutt JG and Ransom BR:
Parkinson’s disease. Lancet. 363:1783–1793. 2004.
|
|
2
|
Chaudhuri KR, Healy DG and Schapira AH:
Non-motor symptoms of Parkinson’s disease: diagnosis and
management. Lancet Neurol. 5:235–245. 2006.
|
|
3
|
Fahn S, Oakes D, Shoulson I, et al:
Levodopa and the progression of Parkinson’s disease. N Engl J Med.
351:2498–2508. 2004.
|
|
4
|
Olanow CW and Jankovic J: Neuroprotective
therapy in Parkinson’s disease and motor complications: a search
for a pathogenesis-targeted, disease-modifying strategy. Mov
Disord. 20(Suppl 11): 3–10. 2005.
|
|
5
|
Signore AP, Weng Z, Hastings T, et al:
Erythropoietin protects against 6-hydroxydopamine-induced
dopaminergic cell death. J Neurochem. 96:428–443. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Csete M, Rodriguez L, Wilcox M and
Chadalavada S: Erythropoietin receptor is expressed on adult rat
dopaminergic neurons and erythropoietin is neurotrophic in cultured
dopaminergic neuroblasts. Neurosci Lett. 359:124–126. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brines ML, Ghezzi P, Keenan S, et al:
Cerami, Erythropoietin crosses the blood-brain barrier to protect
against experimental brain injury. Proc Natl Acad Sci USA.
97:10526–10531. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wei L, Han BH, Li Y, Keogh CL, Holtzman DM
and Yu SP: Cell death mechanism and protective effect of
erythropoietin after focal ischemia in the whisker-barrel cortex of
neonatal rats. J Pharmacol Exp Ther. 317:109–116. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu D, Mahmood A, Qu C, Goussev A,
Schallert T and Chopp M: Erythropoietin enhances neurogenesis and
restores spatial memory in rats after traumatic brain injury. J
Neurotrauma. 22:1011–1017. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Celik M, Gökmen N, Erbayraktar S, et al:
Erythropoietin prevents motor neuron apoptosis and neurologic
disability in experimental spinal cord ischemic injury. Proc Natl
Acad Sci USA. 99:2258–2263. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang LJ, Xue YQ, Yang C, Yang WH, Chen L,
Zhang QJ, Qu TY, Huang S, Zhao LR, Wang XM and Duan WM: Human
albumin prevents 6-hydroxydopamine-induced loss of tyrosine
hydroxylase in in vitro and in vivo. PLoS One. 7:e412262012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xue YQ, Zhao LR, Guo WP and Duan WM:
Intrastriatal administration of erythropoietin protects
dopaminergic neurons and improves neurobehavioral outcome in a rat
model of Parkinson’s disease. Neuroscience. 146:1245–1258.
2007.PubMed/NCBI
|
|
13
|
Paxinos G and Watson C: The Rat Brain in
Stereotaxic Coordinates. 6th edition. Amsterdam: Academic
Press/Elsevier; pp. 2212007
|
|
14
|
Woodlee MT, Asseo-García AM, Zhao X, Liu
SJ, Jones TA and Schallert T: Testing forelimb placing ‘across the
midline’ reveals distinct, lesion-dependent patterns of recovery in
rats. Exp Neurol. 191:310–317. 2005.
|
|
15
|
Ziegler M and Szechtman H: Differences in
the behavioral profile of circling under amphetamine and
apomorphine in rats with unilateral lesions of the substantia
nigra. Behav Neurosci. 102:276–288. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pegg CC, He C, Stroink AR, Kattner KA and
Wang CX: Technique for collection of cerebrospinal fluid from the
cisterna magna in rat. J Neurosci Methods. 187:8–12. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Martin AB, Fernandez-Espejo E, Ferrer B,
et al: Expression and function of CB1receptor in the rat
striatum: localization and effects on D1and
D2dopamine receptor-mediated motor behaviors.
Neuropsychopharmacology. 33:1667–1679. 2008.PubMed/NCBI
|
|
18
|
Granado N, Lastres-Becker I, Ares-Santos
S, et al: Nrf2 deficiency potentiates methamphetamine-induced
dopaminergic axonal damage and gliosis in the striatum. Glia.
59:1850–1863. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Tan CC, Eckardt KU, Firth JD and Ratcliffe
PJ: Feedback modulation of renal and hepatic erythropoietin mRNA in
response to graded anemia and hypoxia. Am J Physiol. 263:F474–F481.
1992.PubMed/NCBI
|
|
20
|
Marti HH, Wenger RH, Rivas LA, et al:
Erythropoietin gene expression in human, monkey and murine brain.
Eur J Neurosci. 8:666–676. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Juul SE, Yachnis AT, Rojiani AM and
Christensen RD: Immunohistochemical localization of erythropoietin
and its receptor in the developing human brain. Pediatr Dev Pathol.
2:148–158. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nagai A, Nakagawa E, Choi HB, Hatori K,
Kobayashi S and Kim SU: Erythropoietin and erythropoietin receptors
in human CNS neurons, astrocytes, microglia, and oligodendrocytes
grown in culture. J Neuropathol Exp Neurol. 60:386–392.
2001.PubMed/NCBI
|
|
23
|
Knabe W, Knerlich F, Washausen S, et al:
Expression patterns of erythropoietin and its receptor in the
developing midbrain. Anat Embryol (Berl). 207:503–512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Digicaylioglu M, Bichet S, Marti HH, et
al: Localization of specific erythropoietin binding sites in
defined areas of the mouse brain. Proc Natl Acad Sci USA.
92:3717–3720. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xue YQ, Ma BF, Zhao LR, et al:
AAV9-mediated erythropoietin gene delivery into the brain protects
nigral dopaminergic neurons in a rat model of Parkinson’s disease.
Gene Ther. 17:83–94. 2010.PubMed/NCBI
|
|
26
|
McLeod M, Hong M, Mukhida K, Sadi D,
Ulalia R and Mendez I: Erythropoietin and GDNF enhance ventral
mesencephalic fiber outgrowth and capillary proliferation following
neural transplantation in a rodent model of Parkinson’s disease.
Eur J Neurosci. 24:361–370. 2006.
|
|
27
|
Zhang F, Signore AP, Zhou Z, Wang S, Cao G
and Chen J: Erythropoietin protects CA1 neurons against global
cerebral ischemia in rat: potential signaling mechanisms. J
Neurosci Res. 83:1241–1251. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kadota T, Shingo T, Yasuhara T, et al:
Continuous intraventricular infusion of erythropoietin exerts
neuroprotective/rescue effects upon Parkinson’s disease model of
rats with enhanced neurogenesis. Brain Res. 1254:120–127.
2009.PubMed/NCBI
|
|
29
|
Lieutaud T, Andrews PJ, Rhodes JK and
Williamson R: Characterization of the pharmacokinetics of human
recombinant erythropoietin in blood and brain when administered
immediately after lateral fluid percussion brain injury and its
pharmacodynamic effects on IL-1beta and MIP-2 in rats. J
Neurotrauma. 25:1179–1185. 2008. View Article : Google Scholar
|
|
30
|
Statler PA, McPherson RJ, Bauer LA,
Kellert BA and Juul SE: Pharmacokinetics of high-dose recombinant
erythropoietin in plasma and brain of neonatal rats. Pediatr Res.
61:671–675. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Xenocostas A, Cheung WK, Farrell F, et al:
The pharmacokinetics of erythropoietin in the cerebrospinal fluid
after intravenous administration of recombinant human
erythropoietin. Eur J Clin Pharmacol. 61:189–195. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yamada M, Burke C, Colditz P, Johnson DW
and Gobe GC: Erythropoietin protects against apoptosis and
increases expression of non-neuronal cell markers in the
hypoxia-injured developing brain. J Pathol. 224:101–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sifringer M, Brait D, Weichelt U, et al:
Erythropoietin attenuates hyperoxia-induced oxidative stress in the
developing rat brain. Brain Behav Immun. 24:792–799. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Aluf Y, Vaya J, Khatib S, Loboda Y,
Kizhner S and Finberg JP: Specific oxidative stress profile
associated with partial striatal dopaminergic depletion by
6-hydroxydopamine as assessed by a novel multifunctional marker
molecule. Free Radic Res. 44:635–644. 2010. View Article : Google Scholar
|
|
35
|
Lee JY, Koh HC, Chang MY, Park CH, Lee YS
and Lee SH: Erythropoietin and bone morphogenetic protein 7 mediate
ascorbate-induced dopaminergic differentiation from embryonic
mesencephalic precursors. Neuroreport. 14:1401–1404. 2003.
|
|
36
|
Yamamoto M, Koshimura K, Kawaguchi M,
Sohmiya M, Murakami Y and Kato Y: Stimulating effect of
erythropoietin on the release of dopamine and acetylcholine from
the rat brain slice. Neurosci Lett. 292:131–133. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Leist M, Ghezzi P, Grasso G, et al:
Derivatives of erythropoietin that are tissue protective but not
erythropoietic. Science. 305:239–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao W, Kitidis C, Fleming MD, Lodish HF
and Ghaffari S: Erythropoietin stimulates phosphorylation and
activation of GATA-1 via the PI3-kinase/AKT signaling pathway.
Blood. 107:907–915. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Um M and Lodish HF: Antiapoptotic effects
of erythropoietin in differentiated neuroblastoma SH-SY5Y cells
require activation of both the STAT5 and AKT signaling pathways. J
Biol Chem. 281:5648–5656. 2006. View Article : Google Scholar
|
|
40
|
Rodriguez-Blanco J, Martin V, Herrera F,
Garcia-Santos G, Antolin I and Rodriguez C: Intracellular signaling
pathways involved in post-mitotic dopaminergic PC12 cell death
induced by 6-hydroxydopamine. J Neurochem. 107:127–140. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Baines CP, Zhang J, Wang GW, et al:
Mitochondrial PKCepsilon and MAPK form signaling modules in the
murine heart: enhanced mitochondrial PKCepsilon-MAPK interactions
and differential MAPK activation in PKCepsilon-induced
cardioprotection. Circ Res. 90:390–397. 2002. View Article : Google Scholar
|
|
42
|
Zhuang S and Schnellmann RG: A
death-promoting role for extracellular signal-regulated kinase. J
Pharmacol Exp Ther. 319:991–997. 2006. View Article : Google Scholar
|
|
43
|
Pan J, Zhao YX, Wang ZQ, Jin L, Sun ZK and
Chen SD: Expression of FasL and its interaction with Fas are
mediated by c-Jun N-terminal kinase (JNK) pathway in 6-OHDA-induced
rat model of Parkinson disease. Neurosci Lett. 428:82–87. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wu SS and Frucht SJ: Treatment of
Parkinson’s disease: what’s on the horizon? CNS Drugs. 19:723–743.
2005.
|
|
45
|
Fyhrquist N, Matikainen S and Lauerma A:
MK2 signaling: lessons on tissue specificity in modulation of
inflammation. J Invest Dermatol. 130:342–344. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lapchak PA: Carbamylated erythropoietin to
treat neuronal injury: new development strategies. Expert Opin
Investig Drugs. 17:1175–1186. 2008. View Article : Google Scholar : PubMed/NCBI
|
